The US Supreme Court will hear arguments in December in the Purdue Pharma case over whether the Bankruptcy Code allows a Chapter 11 plan to provide nonconsensual releases to nondebtor third parties.
The case has the attention of both the general public and bankruptcy practitioners. It involves a multibillion dollar settlement with a wealthy family for their alleged involvement in the opioid epidemic, and also promises to be one of the most consequential Supreme Court opinions on bankruptcy in over a decade, bringing changes to Chapter 11 bankruptcy practice.
Purdue Pharma: A Brief History
Purdue Pharma LP and its ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.